{"id":"W2992921938","doi":"10.1016/s1470-2045(19)30671-0","title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Pembrolizumab; Tolerability; Interim analysis; Refractory (planetary science); Internal medicine; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Adverse effect; Clinical trial; Phases of clinical research; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00287836,0.0009086537,0.001838932,0.0002200671,0.000311592,0.0009808214,0.0006450524,0.0009677814,0.0022698],"category_scores_gemma":[0.002019327,0.0003759215,0.001911401,0.0003524594,0.0006984283,0.001082672,0.0004684819,0.003680033,0.0005004163],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009996869,"about_ca_system_score_gemma":0.00173801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008419401,"about_ca_topic_score_gemma":0.002530241,"domain_scores_codex":[0.9991692,0.0004933053,0.00004758976,0.0001112148,0.0000534984,0.0001251065],"domain_scores_gemma":[0.9988686,0.0002948194,0.0003634729,0.0001073129,0.00005139959,0.0003144468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.800874,0.01079555,0.01192651,0.001485191,0.004853432,0.0004983143,0.000336328,0.00324877,0.01061921,0.0006839593,0.00547648,0.1492023],"study_design_scores_gemma":[0.7514601,0.1958838,0.03395551,0.000318246,0.002509187,0.0008766676,0.0001423993,0.001427994,0.003899938,0.0006741689,0.008799914,0.00005210824],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864141,0.007891785,0.0006269087,0.0009931063,0.0001879722,0.0007468081,0.001303907,0.00005138231,0.001784002],"genre_scores_gemma":[0.9846584,0.005789376,0.002515201,0.001438161,0.0001813303,0.001287838,0.002712351,0.00002590675,0.001391401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00287836,"threshold_uncertainty_score":0.01522237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0939061329066039,"score_gpt":0.4336228266562593,"score_spread":0.3397166937496554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}